問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


China Medical University Hospital (在職)

Division of General Internal Medicine

Division of Endocrinology

更新時間：2023-09-19

王子源
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

0Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

王子源

China Medical University Hospital

Division of Endocrinology

List

17Cases

2010-04-01 - 2011-12-31

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2014-01-01 - 2015-02-27

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2012-12-01 - 2015-11-30

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2008-12-01 - 2009-12-31

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2009-01-15 - 2010-01-31

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2013-04-01 - 2015-06-30

Phase III

A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF ALEGLITAZAR MONOTHERAPY COMPARED WITH PLACEBO IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2D) WHO ARE DRUG-NAÏVE TO ANTI-HYPERGLYCEMIC THERAPY

  • Condition/Disease

    TYPE 2 DIABETES

  • Test Drug

    Aleglitazar (RO0728804)

Participate Sites
3Sites

Terminated3Sites

2017-10-01 - 2021-03-31

Phase II

A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of CS02 Tablet in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Alone

  • Condition/Disease

    Type 2 Diabetes Mellitus

  • Test Drug

    CS02 Tablet

Participate Sites
13Sites

Recruiting2Sites

Terminated10Sites

陳清助
China Medical University Hospital-Taipei

未分科

陳涵栩
Taipei Veterans General Hospital

Division of Endocrinology

2011-09-01 - 2012-07-31

Phase II

RADAR: Reducing Residual Albuminuria in Subjects with Diabetes and Nephropathy with Atrasentan- A Phase 2b, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate Safety and Efficacy

  • Condition/Disease

    Reduce residual albuminuria in patients with diabetes and kidney disease

  • Test Drug

    ABT-627

Participate Sites
3Sites

Terminated3Sites

2019-12-01 - 2025-05-31

Phase III

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease

  • Condition/Disease

    Moderate to Advanced Diabetic Kidney Disease

  • Test Drug

    Selonsertib

Participate Sites
2Sites

Terminated2Sites

2014-07-31 - 2014-09-30

Phase III

An open-label, randomized, multi-center, parallel grouped clinical trial comparing the efficacy and safety of Mylan's Insulin Glargine and Lantus® for patients with type 2 diabetes.

  • Condition/Disease

    Type 2 diabetes

  • Test Drug

    Mylan′s Insulin Glargine

Participate Sites
7Sites

Terminated7Sites

1 2
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB